FDA
-
-
-
-
-
-
-
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
-
-
-
-
-
-
-
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
-
-
-
-
-
-
-
X4 Pharmaceuticals (XFOR) Announces $125M Capital Infusion
-
-
-
-
-
-
-
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program
-
-
-
-
-
-
-
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update
-
322,898 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

